IPF comprises a group of lung diseases that damage the lung by unproven cause, however, genetic susceptibility has been found to account for 35 to 40% of cases. Considering no curative therapy is available, it affects approximately ~132,000 people in the US with about ~50,000 new diagnoses every year.
Comprehensive insight on patient segmentation based on Age group, Sex, Stage (Mild, Moderate & Severe), Genetic factors (MUC5B gene, SFTP-C gene, TERT, and TERC gene, etc.) has been provided into the epidemiology (Incidence and Prevalence) section of the IPF and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
Despite the approval of two antifibrotic drugs that slow the progression of IPF, the prognosis for patients with IPF remains poor. Some key assets like GLPG 1690; Galapagos oral selective and potent autotoxin (ATX) inhibitor targets lysophosphatidic acid (LPA), BMS-986020; BMS is an oral antagonist of LPA receptor 1 (LPA1), BG00011/ STX100; Biogen monoclonal IgG1 antibody which selectively binds to ?v?6, FG-3019; FibroGen humanized monoclonal antibody that inhibits the activity of CTGF. TD139; Galecto Biotech regulates the expression of TGF-? receptors. Apart from this companies like Asahi Kasei (Thrombomodulin Alfa), Kadmon (KD025), Promedior (PRM151), MediciNova (Tipelukast), Celgene (CC 90001), Prometic Biosciences (PBI-4050), Afferent (MK-7264), Morphosys (VAY 736), LTT-BiopPharm (LT-1001 & LT-1002), are actively pursuing the opportunity in the global IPF market.
About Thelansis:
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Other Reports:-
Niemann-Pick Type C (NPC) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Contact details:-
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
clientsupport@thelansis.com
m.berg@thelansis.com
Contact Information:
m.berg@thelansis.com
Tags:
Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English